Nanomedic clears UK NHS hurdle, targets US FDA and Indian markets

Fischer Medical Ventures Ltd. (FMVL) announced on October 23, 2025, that its portfolio company, Nanomedic Technologies Ltd., has successfully registered its SpinCare® solution with the UK's National Health Service (NHS). This achievement enables collaboration with a major London hospital and expands Nanomedic's advanced wound care solution approval to 34 countries across Europe, South America, and Asia.

In India, Nanomedic has completed documentation for SpinCare® registration and secured a license from the Central Drug Standard Control Organization (CDSCO) for clinical investigations and trials. The application for the MD 15 license, required for commercial import, is pending final CDSCO approval. Nanomedic has also engaged with major Indian hospitals for burn injury and chronic wound management.

Nanomedic is reinforcing its operational and regulatory structure, completing Phase One of its MDR/MDD audits for CE certification renewal. Phase Two is scheduled for October 15, 2025. The company has strengthened its leadership team and is preparing SpinCare®'s next FDA filing, with an outcome meeting expected in Q4 2025. Clinical validations for SpinCare® include a retrospective cohort study on pediatric burns and a Stanford University pilot study on epidermolysis bullosa.